|
GB201019775D0
|
|
Pharmaceutical composition
|
|
GB201019774D0
|
|
Medicaments
|
|
GB0916332D0
|
|
Medicaments
|
|
GB0916333D0
|
|
Improvement of tendon repair
|
|
GB0916334D0
|
|
Inhibition of tendon adhesions
|
|
GB0910078D0
|
|
Uses of mannose-6-phosphate
|
|
CA2709007A1
|
|
Methods for inhibiting scarring
|
|
GB0821941D0
|
|
Non-surgical improvements of scars
|
|
GB0812003D0
|
|
Methods and systems for determining efficacy of medicaments.
|
|
GB0810063D0
|
|
Medicaments and methods for inhibition of scarring
|
|
WO2008078074A1
|
|
Promotion of wound contraction with a compound that promotes oestrogenic activity
|
|
WO2008078073A1
|
|
Medicaments and methods comprising a compound that promotes oestrogenic activity for wound healing
|
|
GB0724204D0
|
|
Methods for inhibition of scarring
|
|
GB0724203D0
|
|
Methods for the inhibition of scarring
|
|
TW200837050A
|
|
Protein folding
|
|
TW200837078A
|
|
Medicaments and proteins
|
|
TW200837077A
|
|
Proteins, nucleic acids and medicaments
|
|
GB0714934D0
|
|
Medicaments and methods for inhibition of scarring
|
|
AU2007242586A1
|
|
Use of antagonists of CXCL13 or CXCR5 for treating wounds or fibrotic diseases
|
|
GB0707347D0
|
|
Medicaments and methods for accelerating wound healing
|
